Notably, combined ATR and PARP inhibition has been reported to destabilize stalled replication forks and exhibit synergistic toxicity to tumour cells53,54, and it may be a potential targeted therapy for high ANGscore osteosarcoma population. The gene discussed is ATR; the disease is osteosarcoma.